Mitokinin, Inc.
Small molecule therapeutics that amplify PINK1 kinase activity to enhance mitochondrial quality control and autophagy in Parkinson's disease.
- Sector
- Biotech
- Headquarters
- NEW YORK, NY
- Founded
- 2017
- Latest Form D
- $5M, Nov 2018
- Total capital
- $9.8M
- Federal grants
- $225K
- 1 award · 2018
- Rank in peer group#254 of 392
- Private capital raised
- $9.5M
- 2 Form D · last Nov 2018
- 95 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 29 pending · first 2019
- Rank in peer group#25 of 392
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$5M
- Federal grantHealth and Human S · Phase I · Neo-Substrate Amplifiers of PINK1 for the Treatment of Parkinsons Disease$225K
- Private capital raisedForm D · SEC · 1st filing$4.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#25 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Nicholas HertzResearcherDirectorLinked by 1 patent
- Daniel de Roulet, Jr.Executive Officer, DirectorNamed in SEC Form D filings
- Doug CrawfordDirectorNamed in SEC Form D filings
- Douglas CrawfordDirectorNamed in SEC Form D filings
- Johannes FruehaufDirectorNamed in SEC Form D filings
- Peter ParkerDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 34- PendingCompositions And Methods Of Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseUSPTOApplication 19088609
- PendingCompositions And Methods Of Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseUSPTOApplication 18684942
- PendingCompositions And Methods Of Treating Kidney Disease And FibrosisUSPTOApplication 18029872
Show all 34 patent records
- Compositions And Methods Of Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseAug 7, 2025 · Application 19088609Pending
- Compositions And Methods Of Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseApr 24, 2025 · Application 18684942Pending
- Compositions And Methods Of Treating Kidney Disease And FibrosisDec 5, 2024 · Application 18029872Pending
- Compositions And Methods Of Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseNov 14, 2024 · Application 18684939Pending
- Compositions And Methods Of Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseJan 18, 2024 · Application 17801450Pending
- Compositions And Methods For Treating Neurodegenerative Diseases And CardiomyopathyAug 30, 2022 · US 11,427,588Granted
- Substituted Purines For The Treatment Of Neurodegenerative And Mitochondrial DiseasesAug 16, 2022 · US 11,414,419Granted
- Compositions And Methods Of Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseMay 26, 2022 · Application 17601372Pending
- Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial DiseaseApr 15, 2021 · Application 17063314Pending
- Compositions And Methods Of Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseDec 1, 2020 · US 10,851,109Granted
- Compositions And Methods For Treating Neurodegenerative Diseases And CardiomyopathyJul 28, 2020 · US 10,723,737Granted
- Compositions And Methods Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseJan 1, 2019 · US 10,167,286Granted
- Compositions And Methods For Treating Neurodegenerative Diseases And CardiomyopathyApr 21, 2016 · Application 14823934Pending
- Compositions And Methods Of Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseApplication 63235549Pending
- Compositions And Methods Of Treating Kidney Disease And FibrosisApplication 63087168Pending
- Direct Synthesis Of N-(3-SUBSTITUTED-CHROMAN-4-YL)-7HPYRROLO[2,3-D]PYRIMIDIN-4-AMINES And Derivatives ThereofApplication PCTUS2023072592Pending
- Compositions And Methods Of Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseApplication PCTUS2020026732Pending
- Compositions And Methods Of Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseApplication 62980143Pending
- Compositions And Methods Of Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseApplication 62933632Pending
- Compositions And Methods Of Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseApplication 62879794Pending
- Compositions And Methods Of Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseApplication 62828995Pending
- Direct Synthesis Of N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES And Derivatives ThereofApplication 19104963Pending
- Compositions Methods Using The Same For Treatment For Neurodegenerative And Mitochondrial DiseaseApplication PCTUS2018038756Pending
- Compositions And Methods Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseApplication 62522840Pending
- Compositions And Methods Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseApplication PCTUS2015015513Pending
- Compositions And Methods Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseApplication 61938691Pending
- Disubstituted Benzoimidazole And Indole Analogs As Modulators Of PINK1Application PCTUS2023072587Pending
- Compositions And Methods For Treating Neurodegenerative Diseases And CardiomyopathyApplication PCTUS2014015863Pending
- Compositions And Methods Of Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseApplication PCTUS2022075251Pending
- Compositions And Methods Of Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseApplication PCTUS2022075250Pending
- Direct Synthesis Of N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINES And Derivatives ThereofApplication 63399504Pending
- Disubstituted Benzoimidazole And Indole Analogs As Modulators Of PINK1Application 63399526Pending
- Compositions And Methods Of Treating Kidney Disease And FibrosisApplication PCTUS2021053358Pending
- Compositions And Methods Of Using The Same For Treatment Of Neurodegenerative And Mitochondrial DiseaseApplication 63235575Pending
Related companies, and why
- Novan, Inc.Similar federal contract value in Biotech · null in contracts
- AXONIS THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- KIYATEC, LLCSimilar federal contract value in Biotech · null in contracts
- Suono Bio Inc.Similar federal contract value in Biotech · null in contracts
- EnBiotix, Inc.Similar federal contract value in Biotech · null in contracts
- MIMIVAX, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .